Vaxcyte PCVX 深 滬
等待開盤 09-27 09:30:00 美东时间
33.98
+1.840
+5.72%
華盛通- 最 高34.11
- 今 開32.33
- 成交量 200.00万股
- 最 低 31.89
- 昨 收 32.14
- 總市值 43.83亿
- 52周最高 118.62
- 市盈率 靜 --
- 換手率 1.55%
- 52周最低 27.66
- 委 比 -59.81%
- 總股本 1.29亿
- 歷史最高 121.055
- 量 比 0.82
- 振 幅 6.91%
- 歷史最低 15.51
- 每 手 1
- 風險率 18.57%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅280.95%！HC Wainwright & Co.上调Immix Biopharma目标价至8美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从7美元升至8美元；Maxim Group：上调CNS Pharma评级至"买入"，目标价20美元
09-15 11:13
Goldman Sachs Initiates Coverage On Vaxcyte with Neutral Rating, Announces Price Target of $38
Goldman Sachs analyst Asad Haider initiates coverage on Vaxcyte (NASDAQ:PCVX) with a Neutral rating and announces Price Target of $38.
09-12 23:32
Merck Advances Childhood Pneumococcal Care With Promising Vaccine Data
Merck's Capvaxive vaccine showed strong immune responses and a comparable safety profile to PPSV23 in high-risk children during the Phase 3 STRIDE-13 trial.
09-11 22:23
Vaxcyte Advances Study of New Vaccine for Pneumococcal Disease in Infants, Pegtibatinase Maintained Significant Reductions in Toxic Metabolites
Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced advancement of the modified
09-03 19:33
Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose
Vaxcyte advances its VAX-31 infant Phase 2 study to evaluate the optimized dose of the 31-valent pneumococcal conjugate vaccine candidate designed to prevent invasive pneumococcal disease in infants. The optimized dose includes most serotypes at 4.4mcg and the balance at 3.3mcg, aiming to elicit stronger immune responses. The study, which now includes the optimized dose arm, will provide topline data by the end of the first half of 2027. VAX-31 i...
09-03 11:30
Shares of vaccine companies are trading lower following a Daily Beast report suggesting that President Trump and Health and Human Services Robert F. Kennedy, Jr. will ban Covid-19 vaccines "within months." Also, a report suggested that a Covid-19 vaccine skeptic will lead the Covid-19 immunization task force.
Shares of vaccine companies are trading lower following a Daily Beast report su...
08-26 01:50
Vaxcyte shares are trading lower after the company reported a Q2 EPS miss.
Vaxcyte shares are trading lower after the company reported a Q2 EPS miss.
08-07 04:57
FDA's Vinayak Prasad Says No High-Quality Evidence For Benefit Of Vaccinating People Around Immunocompromised People With Covid Shots; I Don't Envision Randomized Trials Every Year For Covid Vaccines But Rather When There's Major Antigenic Shift
https://x.com/US_FDA/status/1924871996216951112
05-21 01:20
Vaxcyte shares are trading higher after the company reported better-than-expected Q1 EPS results.
Vaxcyte shares are trading higher after the company reported better-than-expect...
05-08 22:53
Vaxcyte Q1 EPS $(1.04) Beats $(1.11) Estimate
Vaxcyte (NASDAQ:PCVX) reported quarterly losses of $(1.04) per share which beat the analyst consensus estimate of $(1.11) by 6.31 percent. This is a 22.35 percent decrease over losses of $(0.85) per share from the same
05-08 04:48
